Intensive glucose control showed no clear difference in all‐cause mortality compared with conventional glucose control (moderate certainty).
The review found no eligible studies for this question.
Intensive glucose control leads to lower manifestation of retinopathy compared with conventional glucose control (high certainty).
Intensive glucose control probably leads to lower progression of retinopathy compared with conventional glucose control (moderate certainty).
Intensive glucose control probably leads to lower manifestation of nephropathy compared with conventional glucose control (moderate certainty).
It is very uncertain whether intensive glucose control changes progression of nephropathy compared with conventional glucose control (very low certainty).
Intensive glucose control leads to lower manifestation of neuropathy compared with conventional glucose control (high certainty).
The review found no eligible studies for this question.
Intensive glycaemic control showed no clear difference in mortality compared with standard glycaemic control (moderate certainty).
Intensive glycaemic control showed no clear difference in cardiovascular mortality compared with conventional glycaemic control (moderate certainty).
Intensive glycaemic control probably leads to lower non‐fatal myocardial infarction compared with conventional glycaemic control (moderate certainty).
Intensive glycaemic control showed no clear difference in non‐fatal stroke compared with conventional glycaemic control (moderate certainty).
Intensive glycaemic control may leads to lower amputation of lower extremity compared with conventional glycaemic control (low certainty).
Intensive glycaemic control showed no clear difference in end‐stage renal disease compared with conventional glycaemic control (moderate certainty).
Intensive glycaemic control leads to higher hypoglycaemia ‐ Severe hypoglycaemia compared with conventional glycaemic control (high certainty).
Angiotensin receptor blockers may leads to lower doubling of SCr Median compared with placebo or no treatment (low certainty).
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with placebo or no treatment (low certainty).
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).